trending Market Intelligence /marketintelligence/en/news-insights/trending/lgQuAtZH6ZiGpBArFoH36g2 content esgSubNav
Log in to other products

 /


Looking for more?

Contact Us
In This List

PhaseBio Pharmaceuticals appoints director

Blog

Highlighting the Top Regional Aftermarket Research Brokers by Sector Coverage

Video

COVID-19 Impact & Recovery: Healthcare Outlook for H2 2021

Blog

Corporate Credit Risk Trends in Developing Markets: A Loss Given Default (LGD) Perspective

Blog

Corporate Credit Risk Trends in Developing Markets: A Probability of Default Perspective


PhaseBio Pharmaceuticals appoints director

PhaseBio Pharmaceuticals Inc. appointed Edmund Harrigan to its board, effective Dec. 13.

Harrigan is also a board member of Bellicum Pharmaceuticals Inc., Karuna Pharmaceuticals Inc, ACADIA Pharmaceuticals Inc. and Lyndra Therapeutics.

PhaseBio Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat orphan diseases.